MARKET

LIFE

LIFE

aTyr Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.05
+0.06
+1.00%
After Hours: 6.05 0 0.00% 17:04 01/24 EST
OPEN
5.81
PREV CLOSE
5.99
HIGH
6.14
LOW
5.34
VOLUME
256.14K
TURNOVER
--
52 WEEK HIGH
13.10
52 WEEK LOW
3.480
MARKET CAP
168.13M
P/E (TTM)
-2.9765
1D
5D
1M
3M
1Y
5Y
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator f...
Benzinga · 5d ago
aTyr Pharma's lung disease drug ATYR1923 named efzofitimod
aTyr Pharma (NASDAQ:LIFE) said the U.S. Adopted Names (USAN) Council and the World Health Organization’s (WHO) International Nonproprietary Name (INN) expert committee have selected the nonproprietary name efzofitimod for ATYR1923, which
Seekingalpha · 01/13 14:16
BRIEF-aTyr Pharma Advances Development Of Lead Therapeutic Candidate ATYR1923 With Announcement Of 'Efzofitimod' As Nonproprietary Name
reuters.com · 01/13 13:17
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medic...
GlobeNewswire · 01/13 13:03
BRIEF-ATyr Pharma Announces FDA Orphan Drug Designation For ATYR1923 For Treatment Of Sarcoidosis
reuters.com · 01/06 14:29
aTyr Pharma's ATYR1923 an Orphan Drug in U.S. for sarcoidosis
aTyr Pharma (NASDAQ:LIFE) perks up 2.5% premarket after announcing that the FDA has granted Orphan Drug Designation for its lead therapeutic candidate, ATYR1923, for the treatment of sarcoidosis. Among the benefits of Orphan Drug
Seekingalpha · 01/06 14:21
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
Company expects to initiate registrational trial of ATYR1923 in pulmonary sarcoidosis in 2022SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of...
GlobeNewswire · 01/06 13:00
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Jill Broadfoot, Chief Financi...
GlobeNewswire · 01/04 13:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LIFE. Analyze the recent business situations of aTyr Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
85.71%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LIFE stock price target is 18.71 with a high estimate of 22.00 and a low estimate of 11.00.
High22.00
Average18.71
Low11.00
Current 6.05
EPS
Actual
Estimate
-0.66-0.49-0.33-0.16
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 57
Institutional Holdings: 19.60M
% Owned: 70.51%
Shares Outstanding: 27.79M
TypeInstitutionsShares
Increased
17
7.76M
New
17
4.56M
Decreased
5
215.79K
Sold Out
4
58.15K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Non-Executive Chairman/Independent Director
John Clarke
President/Chief Executive Officer/Director
Sanjay Shukla
Chief Financial Officer
Jill Broadfoot
General Counsel/Secretary
Nancy Denyes
Director
Sara Zaknoen
Independent Director
Timothy Coughlin
Independent Director
Jane Gross
Independent Director
Svetlana Lucas
Independent Director
Paul Schimmel
No Data
About LIFE
aTyr Pharma Inc is a biotechnology company. The Company’s programs include ATYR1923, ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. It is developing ATYR1923 as a disease-modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need, which include interstitial lung disease (ILD), a group of rare immune-mediated disorders that can cause progressive fibrosis of the lung. ATYR2810, is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands, VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive solid tumors where NRP2 is implicated. The Company is also advancing its preclinical pipeline of tRNA synthetases and NRP2 targeting antibodies through internal research efforts and academic collaborations.

Webull offers kinds of aTyr Pharma Inc stock information, including NASDAQ:LIFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIFE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LIFE stock methods without spending real money on the virtual paper trading platform.